Search 

A specialty company located in NJ focusing developing 505b2s and complex generics

Novodiax has develop a technology platform and product line that address unmet needs for rapid and accurate cancer diagnosis, including rapid intraoperative diagnosis for surgical treatments of cancers, rapid presurgical cancer diagnosis through biopsy specimens (Rapid On-Site Evaluation, ROSE), rapid disease diagnosis through liquid biopsy specimens and novel cancer biomarker’s based companion diagnostics (CDx).

Novodiax pioneered a 10-minute ihcDirectTM IHC detection for frozen section technology, which significantly saves time and reduces reagent consumption and costs with easy to use by reducing steps from traditional protocols. This innovated technology has removed many of the time constraining barriers that once prevented application of IHC stains in intraoperative diagnosis and Mohs surgery labs.
Novodiax also provides multiplex IHC detection which accelerates turnaround time, increases instrument productivity and reduces reagent consumption.

In summary Novodiax enjoys the following major strength
1- Novodiax currently offers a 10 min IHC product line that can be used for intraoperative evaluation of frozen tissues and for Rapid On-Site Evaluation (ROSE) of biopsy specimens.
2- Novodiax will launch in Q4 2020 an advanced automation system including a rapid compact IHC stainer and a superfast FFPE tissue pre-treatment device along with tens of ihcDirect® IHC reagents. This affordable system is a perfect solution for any situation where a rapid turnaround time is needed, such as, the rush cases using FFPE tissues in large medical centers. Our 10 min intraoperative and ROSE protocols will be available on the system too.
3- Novodiax products have already been optimized for Leica staining instruments and can be optimized for all automated staining platforms in the market.
4- The rapid turnaround time of Novodiax’s reagents and instruments offers a natural advantage for multiplex applications.

Replace eye drops from FREEDOM drug releasing clear contact lens corneal bandage. The device has a 7 day wear time consistent with the standard of care recall after; cataract, LASIK surgery & corneal abrasion & non infectious Uveitis. Doctor puts device on and takes it off eliminating patient compliance problems with quicker healing with drug constantly treating the target tissue. 10 granted patents with FTO legal opinion. 10 mono and combo ophthalmic Dougs tested. Completed in vivo safety study. Letter and meeting being set with the US FDA for phase 1-2 clinical in January 2021.

My organization, OneThree Biotech, is a company that is dedicating our biology-driven AI expertise towards the fight against cancer. We’re combining systems biology with artificial intelligence to uncover new insights and build the next generation of drug discovery. We’ve built 14 different algorithms into our platform to provide insights across steps like target selection, compound mechanisms, toxicity and metabolism, and patient biomarkers at the beginning of the development process. This not only provides greater mechanistic insights, but also helps ensure a greater success rate for drugs entering preclinical development. Over the course of 2020 our founders have spoken at countless events like the BioData World Congress, Pharma and Patient USA, and various Reuters events culminating in our most recent accomplishment of winning Reuters' Entrepreneur Award for Health Solutions.

OniX invest in companies in two ways: (1) Directly through it OniX Venture Fund and (2) Indirectly through its OniX hub members (includes pharma, VC, PE, family offices and private foundations)

Otomagnetics is a biotechnology Company developing a non-invasive platform technology to deliver drugs and other therapeutic payloads to the inner and middle ear compartments, eye and skin. The link to the explainer video on the technology is provided below.

https://www.youtube.com/watch?v=1go9HYjMlFk&feature=youtu.be

Private investment firm

Cancer Immunotherapy development